exa-cel
Vertex pharmaceuticals,CRISPR therapeutics AG
[]
late breaking #eha2022 crispr #geneediting exa-cel leads to #transfusion independence in 95% patients in thalasssemia &amp; voc free in 100% patients with scd contributed to these trials. #atmps 
Haematology pharmacist, UCLH